Moleculin Biotech reports preliminary data from clinical trial of WP1220
Moleculin Biotech announced it now has preliminary data from its clinical trial of WP1220 for the treatment of cutaneous T-cell lymphoma, which was published in Blood in conjunction with the American Society of Hematology Annual Meeting and Exposition to be held December 7-10. "For years, p-STAT3 has been considered an 'undruggable' target because of the difficulty of reaching and affecting this cell-signaling protein," commented Moleculin biotech. "Some consider it to be a master regulator of cancer-related gene transcription, so we believe the ability to show a therapeutic effect from a p-STAT3 inhibitor could be considered a significant breakthrough in cancer research." There were 6 patients screened, and 5 patients enrolled between March and July. Three are evaluable for both safety and efficacy after completing 3 months of treatment, with 2 ongoing and evaluable for safety. The only AE reported potentially related to study drug in one of the five patients was a mild contact dermatitis not requiring treatment. In summary, according to the company, WP1220, an inhibitor of p-STAT3, has shown demonstrable safety and significant efficacy after at least 3 months of topical treatment in 3 patients with progressive MF, with a continuing trend towards improvement in additional patients currently in treatment.